Abstract:To the Editor: Pulmonary lymphangioleiomyomatosis (LAM) is a rare, progressive disease affecting almost exclusively women that is seen in both patients with tuberous sclerosis complex (TSC) and those without TSC, the latter termed sporadic LAM (S-LAM) (1–5). LAM is characterized by infiltration of the lung parenchyma by neoplastic spindle-shaped cells with combined smooth muscle and melanocytic differentiation, and is associated with both extensive involvement of lymphatic channels by similar cells in nearly all cases, and occurrence of renal angiomyolipoma in 30 to 50% of S-LAM cases (3). Past seminal publications identified mutations and loss of heterozygosity (LOH) in TSC2 in pulmonary LAM cells of four S-LAM patients who had angiomyolipomas with known mutations (6), and in two of five S-LAM patients (7). Other studies have shown that TSC2 mutations are seen in cultured LAM cells (8), and that TSC2 LOH is seen in LAM cells isolated from blood, urine, chylous fluid, and bronchoalveolar lavage fluid in 50 to 90% of S-LAM patients (9, 10). Some of the results of this study have been previously reported in the form of abstracts (11, 12). We searched for TSC2 mutations in 10 S-LAM patients that had lung transplant using a combination of laser capture microdissection (LCM) and next-generation sequencing (NGS) (see online supplement). Examination of formalin-fixed paraffin-embedded sections showed classic features of LAM, with multiple cysts and disseminated LAM nodules, the cells of which were smooth muscle actin (SMA) and HMB45 positive (Figures E8A–E8G in the online supplement). LCM guided by SMA immunohistochemistry was performed on frozen sections to collect LAM cells from nodules (Figure E1) and avoid inclusion of lymphatic channels, lymphocytes, and other cell types (Figures E3 and E4). After DNA extraction and amplification, NGS was performed using either the 454 or Illumina platforms (Reference 13 and online supplement). High read depth was achieved across the coding region of TSC2 (median, 486; >200 in 96% of exons), enabling detection of low-frequency sequence variants. Nine different pathogenic sequence variants were detected in TSC2 in eight different sporadic LAM samples, at frequencies ranging from 4 to 60% (Table 1), with most seen at a frequency less than 20%. All were verified by Sanger or SNaPshot analysis on unamplified DNA (Figures E6 and E7). Four samples showed evidence of two-hit inactivation in TSC2, three of them with a mutation and LOH, and one with two point mutations. The four cases without LOH all had low allele fractions for mutation in TSC2 (≤16%), making detection of LOH difficult. The two LAM samples in which no TSC2 mutation was identified also showed no mutation in TSC1 by NGS sequencing. Significantly, in one of these cases, over 90% of LAM cells were positive for HMB45 (case 9023) (Figure E8B), and in the other, the patient had a concomitant renal angiomyolipoma, providing additional evidence of S-LAM (1, 2). HMB45+ cells in LAM sections have relatively low PCNA expression, suggesting that they are less proliferative than HMB45− cells (14). Although some types of inactivating mutations are missed by exonic sequencing, immunohistochemistry for TSC2 (tuberin) and TSC1 (hamartin) on the two cases without defined mutations showed strong expression of each protein, whereas little or no expression of either was seen in a control case with two mutations in TSC2 (Figure 1 and Figure E10). Furthermore, the two cases without TSC1/TSC2 mutation showed no expression of phospho-S6 kinase by immunohistochemistry, in contrast to cases in which biallelic TSC2 mutations were identified (Figures 1G–1I). This suggests that mechanistic target of rapamycin complex 1 (mTORC1) was not activated in the LAM nodules of these two patients, consistent with normal TSC1/TSC2 function and mTOR regulation. TABLE 1. MUTATIONS AND SINGLE-NUCLEOTIDE POLYMORPHISMS DETECTED IN TSC1 AND TSC2 IN 10 SPORADIC LAM SAMPLES Figure 1. Hamartin and tuberin expression and lack of phosphorylated S6K (p-S6K) expression in lymphangioleiomyomatosis (LAM) nodules from two LAM cases with no mutation identified. Three LAM lesions are shown. (A–D) Two cases, 9023 and 9030, had no mutations ... The occurrence of TSC2 mutations at relatively low frequency, or not at all, in these LAM samples is surprising. As shown here and elsewhere (13), NGS has the capability to detect mutations that are present at a very low allelic fraction, 1% or lower, enabling high sensitivity analyses as performed here. High sample contamination with non-LAM cells seems unlikely given our efforts at histological purification of the cells collected by LCM, the identification of mutations at high frequency in some cases, and the detection of a low- and a high-frequency mutation in one case. It is possible that TSC2 mutations occur in a subset of LAM cells, after other unknown initiating events, and are not the primary driver of LAM development, or TSC2-mutant cells recruit stromal cells to adopt an SMA-positive phenotype. In addition, the two cases without TSC1 or TSC2 mutations identified also suggest that alternative genetic mechanisms may be operative in some cases of LAM. Recently the Multicenter International LAM Efficacy of Sirolimus (MILES) trial demonstrated that rapamycin (sirolimus), an mTORC1 inhibitor that blocks the pathway activated by loss of tuberin (15), was an effective therapy for treatment of LAM (16). However, it is notable that continuing FEV1 decline was seen in 50% of patients on rapamycin therapy. It is possible that some of these nonresponders do not have loss of TSC2 with activation of mTORC1 as a fundamental pathogenic mechanism for LAM development, consistent with our data.

Connectivity Map Analysis of a Single-Cell RNA-Sequencing -Derived Transcriptional Signature of mTOR Signaling

Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of -altered non-small cell lung cancer.

Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor

Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors.

Extracellular Matrix-Induced Genes May Reduce Response to Rapamycin in LAM

Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.

Possible Novel Therapeutic Targets in Lymphangioleiomyomatosis Treatment

Targeting SPHK1/S1PR3-regulated S-1-P Metabolic Disorder Triggers Autophagic Cell Death in Pulmonary Lymphangiomyomatosis (LAM)

Hyperactive mTORC1 in lung mesenchyme induces endothelial cell dysfunction and pulmonary vascular remodeling

Sirolimus Decreases Circulating Lymphangioleiomyomatosis Cells in Patients with Lymphangioleiomyomatosis

Single-cell multiomic analysis identifies a HOX-PBX gene network regulating the survival of lymphangioleiomyomatosis cells

Exonic Mutations of TSC2/TSC1 Are Common but Not Seen in All Sporadic Pulmonary Lymphangioleiomyomatosis

CrossTORC and WNTegration in Disease: Focus on Lymphangioleiomyomatosis

Abstract 3515: Pathway Convergent Evolution Underscores Treatment Response to MTOR Inhibitors in Kidney Cancers.

STAT1 Promotes PD-L1 Activation and Tumor Growth in Lymphangioleiomyomatosis

Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells

Role of the CXCR4/CXCL12 axis in lymphangioleiomyomatosis and angiomyolipoma

Abstract 1670: Mechanistic insight into mTOR signaling identifies RNA splicing machinery as a potential therapeutic target for cancer

Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and an immune-suppressive microenvironment

Adaptive responses to mTOR gene targeting in hematopoietic stem cells reveal a proliferative mechanism evasive to mTOR inhibition.

Targeting Fibroblast-Endothelial Interactions in LAM Pathogenesis: 3D Spheroid and Spatial Transcriptomic Insights for Therapeutic Innovation